Αρχειοθήκη ιστολογίου

Αλέξανδρος Γ. Σφακιανάκης
ΩτοΡινοΛαρυγγολόγος
Αναπαύσεως 5
Άγιος Νικόλαος Κρήτη 72100
2841026182
6032607174

Σάββατο 9 Ιουνίου 2018

Insulin decreases expression of the pro-inflammatory receptor Proteinase-Activated Receptor-2 on human airway epithelial cells

alertIcon.gif

Publication date: Available online 8 June 2018
Source:Journal of Allergy and Clinical Immunology
Author(s): Vivek D. Gandhi, Nami Shrestha Palikhe, Shereen M. Hamza, Jason R.B. Dyck, Jean Buteau, Harissios Vliagoftis

Teaser

The authors show that insulin, a hormone with anti-inflammatory properties, decreases the expression of a pro-inflammatory receptor on airway epithelial cells. This observation may explain the heightened respiratory inflammation seen in patients with metabolic syndrome.


https://ift.tt/2xZ3ZqM

GM-CSF Therapy in Human CARD9 Deficiency

alertIcon.gif

Publication date: Available online 8 June 2018
Source:Journal of Allergy and Clinical Immunology
Author(s): Rebecca A. Drummond, Fatema Tuz Zahra, Mukil Natarajan, Muthulekha Swamydas, Amy P. Hsu, L. Joseph Wheat, Christina Gavino, Donald C. Vinh, Steven H. Holland, Constantinos M. Mikelis, Michail S. Lionakis

Teaser

CARD9 deficiency is associated with life-threatening fungal infections of the CNS. This work shows that the H-RAS/RASGRF1/ERK pathway is intact in the c.170G>A (p.R57H) CARD9 missense mutation, a finding that correlates with the clinical outcome of GM-CSF therapy.


https://ift.tt/2Mdksef

Midostaurin in indolent systemic mastocytosis patients: an open-label phase 2 trial

alertIcon.gif

Publication date: Available online 8 June 2018
Source:Journal of Allergy and Clinical Immunology
Author(s): Bjorn van Anrooij, Joanne N.G. Oude Elberink, L.F. Span, Jan G.R. de Monchy, Stefano Rosati, André B. Mulder, Johanna C. Kluin-Nelemans

Teaser

This is the first report on a trial using a Kit D816V targeting drug in indolent systemic mastocytosis. The results indicate midostaurin to be effective in reducing symptom severity and improving quality of life.


https://ift.tt/2Jv0WYL

A trial of P2Y12 receptor inhibition with prasugrel identifies a potentially distinct endotype of patients with aspirin-exacerbated respiratory disease

Publication date: Available online 8 June 2018
Source:Journal of Allergy and Clinical Immunology
Author(s): Tanya M. Laidlaw, Katherine N. Cahill, Juan Carlos Cardet, Katherine Murphy, Jing Cui, Brittney Dioneda, Parul Kothari, Benjamin A. Raby, Elliot Israel, Joshua Boyce
BackgroundAspirin-exacerbated respiratory disease (AERD) is characterized by asthma, recurrent nasal polyposis, and respiratory reactions upon ingestion of cyclooxygenase-1 inhibitors. Increased numbers of platelet-leukocyte aggregates are present in the sinus tissue and blood of patients with AERD, compared to aspirin-tolerant patients, and platelet activation may contribute to aspirin-induced reactions.ObjectiveWe sought to determine whether treatment with prasugrel, which inhibits platelet activation by blocking the P2Y12 receptor, would attenuate the severity of sinonasal and respiratory symptoms induced during aspirin challenge in subjects with AERD.Methods40 subjects with AERD completed a 10-week, double-blinded, placebo-controlled crossover trial of prasugrel. All subjects underwent oral aspirin challenges after 4 weeks of prasugrel and after 4 weeks of placebo. The primary outcome was a change in the provocative dose of aspirin that would elicit an increase in total nasal symptom score of 2 points (PD2). Changes in lung function, urinary eicosanoids, plasma tryptase, platelet-leukocyte aggregates, and platelet activation were also recorded.ResultsPrasugrel did not significantly change the mean PD2 (79 ±15 on placebo and 139 ±32 on prasugrel, P = 0.10), platelet-leukocyte aggregates, or increases in urinary leukotriene E4 (LTE4) and prostaglandin D2 metabolite (PGD-M) levels during aspirin-induced reactions in the study population as a whole. Five subjects ("responders") reacted to aspirin while on placebo but did not develop any reaction to aspirin challenge after the prasugrel arm. In contrast to prasugrel nonresponders (35 subjects), the prasugrel responders had smaller reaction-induced increases in TNSS, did not show significant aspirin-induced increases in urinary LTE4, PGD-M, or thromboxane B2 levels, and failed to display increases in serum tryptase levels during the aspirin reactions on the placebo arm, all of which were observed in the nonresponders.ConclusionIn the overall study population, prasugrel did not attenuate aspirin-induced symptoms, possibly because it failed to decrease the frequencies of platelet-adherent leukocytes, or to diminish aspirin-induced mast cell activation. In a small subset of patients with AERD who had higher baseline platelet activation and milder upper respiratory symptoms during aspirin reactions, P2Y12 antagonism with prasugrel completely inhibited all aspirin-induced reaction symptoms, suggesting a contribution from P2Y12 signaling in this subset.Clinical ImplicationsP2Y12 antagonism with prasugrel prevents aspirin-induced reactions in only a subset of AERD patients with a component of P2Y12-dependent mechanisms of reaction to aspirin.

Teaser

Platelet activation increased in AERD. In a randomized placebo-controlled cross-over trial, platelet inhibition through P2Y12 antagonism with prasugrel neither prevented nor lessened aspirin-induced reactions in most patients with AERD, though did identify a small subset of responders who may have a distinct P2Y12-dependent mechanism of reaction to aspirin.


https://ift.tt/2JIpUav

A bispecific antibody strategy to target multiple type 2 cytokines in asthma

Publication date: Available online 8 June 2018
Source:Journal of Allergy and Clinical Immunology
Author(s): Marie Godar, Kim Deswarte, Karl Vergote, Michael Saunders, Hans de Haard, Hamida Hammad, Christophe Blanchetot, Bart N. Lambrecht
BackgroundAsthma is a chronic inflammatory airway disease in which innate and adaptive immune cells act together to cause eosinophilic inflammation, goblet cell metaplasia (GCM) and bronchial hyperreactivity (BHR). In clinical trials employing biologicals against interleukin (IL)-4Rα or IL-5, only a subset of moderate-to-severe asthmatics responded favorably, suggesting that distinct pathophysiological mechanisms are at play in subgroups of patients, called endotypes. However, the effect of multiple cytokine blockade using bispecific antibodies (Ab) has not been tested.ObjectiveTo target simultaneously IL-4, IL-13 and IL-5 signaling pathways with a novel IL-4Rα/IL-5 bispecific Ab in a murine house dust mite (HDM) model of asthma.MethodsTwo monoclonal Abs neutralizing IL-4Rα and IL-5 were generated using a llama-based Ab platform. Their heavy (HC) and light chains (LC) where then co-transfected in mammalian cells, resulting in a heterogeneous Ab mixture from which the bispecific Ab was isolated using a dual anti-idiotypic purification process. C57BL/6J mice were finally sensitized and challenged to HDM extracts and treated during challenge with the Abs.ResultsWe successfully generated and characterized the monospecific and bispecific Abs targeting IL-4Rα and IL-5. The monospecific Abs could suppress eosinophilia and/or IgE synthesis whereas only the IL-4Rα/IL-5 bispecific Ab and the combination of monospecific Abs additionally inhibited GCM and BHR.ConclusionType 2 cytokines act synergistically to cause GCM and BHR in HDM-exposed mice.

Teaser

Current asthma biologicals include IL-4Rα and IL-5 monospecific Abs. Here we show the feasibility of producing an anti-IL-4Rα/IL-5 bispecific Ab that neutralizes both targets and demonstrates superior effectiveness in a murine house dust mite model.


https://ift.tt/2xZl8Rg

Blood cell count indexes as predictors of outcomes in advanced non-small-cell lung cancer patients treated with Nivolumab

Abstract

Lung cancer is the most common malignancy worldwide. Despite significant advances in diagnosis and treatment, mortality rates remain extremely high, close to incidence rates. Several targeted therapies have been recently introduced for the treatment of non-small cell lung cancer (NSCLC), the most common type of lung cancer. Nivolumab, a monoclonal antibody that targets programmed death-1 (PD-1), was the first immune checkpoint inhibitor approved for the treatment of patients with advanced/metastatic NSCLC not responding to platinum-based chemotherapy. Biomarkers predicting response to these therapies would allow early identification of non-responders and timely implementation of appropriate combination strategies, avoiding inadequate and expensive therapies. The role of the neutrophil to lymphocyte ratio and other blood cell count indexes as possible biomarkers of response has been recently investigated. We discuss the encouraging results reported on the topic, provide new data from our personal experience, and discuss opportunities for further research.



https://ift.tt/2JuRzs6

Next-Generation of Allergen-Specific Immunotherapies: Molecular Approaches

Abstract

Purpose of Review

The aim of this article is to discuss how allergen-specific immunotherapy (AIT) can be improved through molecular approaches. We provide a summary of next-generation molecular AIT approaches and of their clinical evaluation. Furthermore, we discuss the potential of next generation molecular AIT forms for the treatment of severe manifestations of allergy and mention possible future molecular strategies for the secondary and primary prevention of allergy.

Recent Findings

AIT has important advantages over symptomatic forms of allergy treatment but its further development is limited by the quality of the therapeutic antigen preparations which are derived from natural allergen sources. The field of allergy diagnosis is currently undergoing a dramatic improvement through the use of molecular testing with defined, mainly recombinant allergens which allows high-resolution diagnosis. Several studies demonstrate that molecular testing in early childhood can predict the development of symptomatic allergy later on in life.

Summary

Clinical studies indicate that molecular AIT approaches have the potential to improve therapy of allergic diseases and may be used as allergen-specific forms of secondary and eventually primary prevention for allergy.



https://ift.tt/2sU5r86